Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Post FY2024 Earnings of $37.72 Per Share, Cantor Fitzgerald Forecasts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for Regeneron Pharmaceuticals in a report released on Monday, April 22nd. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will earn $37.72 per share for the year, up from their prior estimate of $37.66. Cantor Fitzgerald has a "Neutral" rating and a $925.00 price objective on the stock. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $38.80 per share.

A number of other equities analysts have also recently issued reports on the stock. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an "underperform" rating in a research report on Friday, April 12th. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Truist Financial reissued a "buy" rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Barclays upped their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an "overweight" rating in a report on Tuesday, January 23rd. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $976.41.

Regeneron Pharmaceuticals Stock Up 0.8 %

Shares of REGN stock traded up $7.16 on Tuesday, reaching $907.32. 336,829 shares of the company were exchanged, compared to its average volume of 491,297. The company has a market cap of $99.59 billion, a price-to-earnings ratio of 25.90, a PEG ratio of 2.58 and a beta of 0.11. The company has a 50-day moving average of $952.07 and a 200-day moving average of $892.70. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. Regeneron Pharmaceuticals has a one year low of $684.80 and a one year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to analysts' expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $10.96 earnings per share.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares of the company's stock, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares of the company's stock, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm's stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares of the company's stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 11,022 shares of company stock valued at $10,552,991 in the last three months. Company insiders own 8.83% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Meyer Handelman Co. boosted its holdings in Regeneron Pharmaceuticals by 11.4% in the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company's stock valued at $3,485,000 after purchasing an additional 435 shares during the period. Stifel Financial Corp boosted its holdings in Regeneron Pharmaceuticals by 12.2% in the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company's stock valued at $25,537,000 after purchasing an additional 3,385 shares during the period. LPL Financial LLC boosted its holdings in Regeneron Pharmaceuticals by 9.3% in the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company's stock valued at $33,522,000 after purchasing an additional 3,479 shares during the period. Cavalier Investments LLC boosted its holdings in Regeneron Pharmaceuticals by 88.6% in the 3rd quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company's stock valued at $3,651,000 after purchasing an additional 2,084 shares during the period. Finally, Exchange Traded Concepts LLC boosted its holdings in Regeneron Pharmaceuticals by 32.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company's stock valued at $4,351,000 after purchasing an additional 1,221 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.